October 28, 2021EP Europace
HeartMate 3: new challenges in ventricular tachycardia ablation
Key result
VT ablation achieves non-inducibility in 58% of HeartMate 3 patients.
- n=19
Why the study?
To describe clinical characteristics, procedural details, specific challenges, and outcomes in patients with HeartMate 3 undergoing ventricular tachycardia ablation.
Is ventricular tachycardia ablation feasible and safe in patients with a HeartMate 3 left ventricular assist device?
Population
19 patients with cardiomyopathy and an HM3 system presenting with VT
Design
Multicentre cohort study across seven tertiary centres
Follow-up
429 (interquartile range 101-692) days
Authors
Discussion
Loading...
Member takes
Implication
Supports VT ablation feasibility in HM3 recipients; leaves open efficacy, safety, and optimal selection in larger prospective studies.
Study Design
Type
Cohort (n=19)
Multicenter
Yes
Structured PICO
Is ventricular tachycardia ablation feasible and safe in patients with a HeartMate 3 left ventricular assist device?
P
Population
19 patients with cardiomyopathy and a HeartMate 3 (HM3) left ventricular assist device presenting with ventricular tachycardia (53% with VT storm)
I
Intervention
Ventricular tachycardia ablation (VTA)
O
Outcome
Mortality and arrhythmia-free survivalhard clinical
Ventricular tachycardia ablation in patients with a HeartMate 3 LVAD is feasible and safe, though it requires specific techniques to overcome electromagnetic interference and imaging challenges.
Cite This Study
Nof et al. (2021) conducted a cohort in Cardiomyopathy with ventricular tachycardia (n=19). Ventricular tachycardia ablation was evaluated on Non-inducibility of any ventricular tachycardia. Ventricular tachycardia ablation in patients with a HeartMate 3 device achieved non-inducibility in 58% of patients, with 26% requiring redo ablation over a median follow-up of 429 days.